טוען...
Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus
Vancomycin has been used as the last resort in the clinical treatment of serious Staphylococcus aureus infections. Vancomycin-intermediate S. aureus (VISA) was discovered almost two decades ago. Aside from the vancomycin-intermediate phenotype, VISA strains from the clinic or laboratory exhibited co...
שמור ב:
| הוצא לאור ב: | Front Microbiol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5062060/ https://ncbi.nlm.nih.gov/pubmed/27790199 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmicb.2016.01601 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|